Spots Global Cancer Trial Database for XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors
Official Title: A Phase III Randomized, Double-Blind, Dexamethasone-Sparing Study Comparing Human Corticotropin-Releasing Factor (hCRF) to Placebo for Control of Symptoms Associated With Peritumoral Brain Edema in Patients With Malignant Brain Tumor Who Require Chronic Administration of High-Dose Dexamethasone
Study ID: NCT00088166
Study Description
Brief Summary: The purpose of this study is to compare the safety and efficacy of XERECEPT® to dexamethasone (Decadron) a common treatment for symptoms of brain swelling (edema). This study is specifically aimed at patients who require chronic high doses of dexamethasone to manage symptoms.
Detailed Description: XERECEPT® is not a potential treatment for cancer, but may reduce the edema associated with tumors and as a result, decrease neurological symptoms.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Barrow Neurological Institute, Phoenix, Arizona, United States
UCSF Fresno Center for Clinical Studies, Fresno, California, United States
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
Stanford University Medical Center, Palo Alto, California, United States
UC Davis Medical Center, Division of Medical Oncology, Sacramento, California, United States
UC San Diego, Thornton Hospital, San Diego, California, United States
University of Colorado Cancer Center, Aurora, Colorado, United States
Colorado Neurological Institute, Englewood, Colorado, United States
Mayo Clinic, Jacksonville, Florida, United States
Cancer Institute of Orlando, Orlando, Florida, United States
Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States
Evanston Northwestern Healthcare, Evanston, Illinois, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit, Michigan, United States
Neurology Group of Bergen County, Ridgewood, New Jersey, United States
Dent Neurologic Institute, Amherst, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Weill Medical College of Cornell University, New York, New York, United States
University Hematology Oncology Care, LLC, Cincinnati, Ohio, United States
Good Samaritan Hospital, Cincinnati, Ohio, United States
The Ohio State University, Columbus, Ohio, United States
Oregon Clinic, Portland, Oregon, United States
Virginia Mason Clinic, Seattle, Washington, United States
University of Wisconsin, Madison, Wisconsin, United States
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Cross Cancer Institute, Edmonton, Alberta, Canada
CancerCare Manitoba, Winnipeg, Manitoba, Canada
The Moncton Hospital, Moncton, New Brunswick, Canada
Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada
Kingston General Hospital, Kingston, Ontario, Canada
Ottawa Regional Cancer Centre, Ottawa, Ontario, Canada
Sunnybrook and Women's College Health, Toronto, Ontario, Canada
Contact Details
Name: William Shapiro, MD
Affiliation: Barrow Neurological Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
